Vosoritide

What is Vosoritide?

Vosoritide is a 39-amino-acid modified analog of human C-type natriuretic peptide (CNP), developed by BioMarin Pharmaceutical and marketed as Voxzogo for the treatment of achondroplasia in children with open growth plates. Achondroplasia is the most common form of disproportionate short stature, caused by a gain-of-function mutation in FGFR3 (fibroblast growth factor receptor 3) that over-represses endochondral bone growth at the growth plate. Vosoritide was designed to counteract this over-active FGFR3 signaling by engaging NPR-B (natriuretic peptide receptor B) on growth-plate chondrocytes, reactivating the natural cartilage-to-bone elongation pathway. The FDA approved Voxzogo in November 2021 for children with achondroplasia aged 5 years and older with open epiphyses, and expanded the indication on October 20, 2023 to children of all ages with open growth plates (the US label sets no minimum age) — making it the first targeted therapy approved for this condition (growth hormone has been used for achondroplasia in Japan since 1997). Families researching vosoritide are typically parents of a child recently diagnosed with achondroplasia weighing a difficult treatment decision. The evidence base is strong by rare-disease standards, and the growth-velocity benefit is real — but the absolute magnitude is modest relative to the difference in adult stature between achondroplasia and average-stature individuals, and long-term outcomes on adult height, cardiovascular, neurological, and orthopedic complications of achondroplasia are still being studied.

What Vosoritide Is Investigated For

Vosoritide is investigated and FDA-approved for achondroplasia in children with open growth plates — the first targeted therapy approved for this condition, initially approved November 2021 for children aged 5 and older and expanded in October 2023 to all ages with open growth plates in the US (4 months and older in the EU); a second CNP-pathway drug, once-weekly navepegritide (YUVIWEL), received US accelerated approval in February 2026 for children 2 and older. The strongest evidence is the pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) in 121 children showing approximately 1.57 cm/year increase in annualized growth velocity versus placebo, supported by open-label extension data showing sustained benefit across several years of continued daily dosing. The mechanism is unusually clean: vosoritide's NPR-B–cGMP pathway activation directly antagonizes the over-active FGFR3-MAPK signaling that causes achondroplasia. The honest caveats are important for families weighing treatment. Vosoritide is not a cure — it does not correct the underlying FGFR3 mutation and the growth-velocity benefit, while statistically significant, is modest relative to the roughly 35 to 45 cm adult height gap between achondroplasia (average adult height about 131 cm in men and 124 cm in women) and average-stature peers. Final adult height data have not yet been published for any treated group (BioMarin's application for full approval, which includes adult-height data, is under FDA review with a target action date of February 28, 2027), effects on non-stature complications (spinal stenosis, foramen magnum stenosis, sleep apnea) remain emerging rather than established, and the decision to treat carries real values considerations within the achondroplasia community.

History & Discovery

The scientific path to vosoritide began with recognition in the 1990s and 2000s that FGFR3 gain-of-function mutations cause achondroplasia and that C-type natriuretic peptide (CNP) signaling, acting through NPR-B and cGMP, is a major positive regulator of endochondral bone growth that opposes FGFR3-MAPK activity. Mouse-genetic work showed that overexpressing CNP in chondrocytes could rescue the achondroplasia phenotype in Fgfr3-mutant animals — a striking proof-of-concept that framed the therapeutic opportunity. Native CNP has a short plasma half-life because neutral endopeptidase (neprilysin) rapidly clears it, making it impractical as a systemic therapeutic. BioMarin Pharmaceutical engineered a modified analog (BMN-111) with an N-terminal extension that resists neprilysin cleavage while preserving NPR-B agonism. BMN-111 advanced through Phase 1 healthy-volunteer studies, a Phase 2 dose-escalation program in children with achondroplasia, and culminated in the pivotal Phase 3 trial (Savarirayan et al., Lancet 2020) that demonstrated the ~1.57 cm/year growth velocity improvement versus placebo over 52 weeks. FDA approved Voxzogo on November 19, 2021 for children with achondroplasia aged 5 and older with open epiphyses — the first targeted therapy approved in the US for this condition. In October 2023 the FDA expanded the indication to children of all ages with open growth plates, based on a randomized placebo-controlled trial in children under 5 plus pharmacokinetic data. The EU actually authorised Voxzogo first, on 26 August 2021, for children aged 2 and older (extended to 4 months and older in late 2023). Japan approved it in 2022 for children from birth, and other regulators followed with differing age criteria. Development was conducted with close engagement from achondroplasia advocacy organizations, particularly Little People of America, whose community holds a range of views on treatment — a context that clinicians and families continue to navigate case by case.

How It Works

Children with achondroplasia have a genetic change in a protein called FGFR3 that makes it too active. Overactive FGFR3 tells the cartilage cells at the growth plates of a child's bones to slow down — which is why achondroplasia causes shorter limbs and shorter overall stature. Vosoritide is a lab-made version of a natural signal called CNP that does the opposite: it tells those same cartilage cells to keep growing normally. By partially counterbalancing the overactive FGFR3 signal, vosoritide helps bones grow longer during childhood, as long as growth plates are still open.

Vosoritide is a modified 39-amino-acid analog of human C-type natriuretic peptide (CNP), the physiological ligand for natriuretic peptide receptor B (NPR-B, also known as NPR2). Native 22-residue CNP is cleared within minutes by neutral endopeptidase (neprilysin). Vosoritide is the 37 C-terminal amino acids of human CNP-53 plus an added Pro-Gly at the N-terminus, which confers neprilysin resistance. Its plasma half-life is still short — about 21 to 28 minutes in children — but NPR-B activation, measured as urinary cGMP, peaks about 2 hours after a dose, supporting once-daily injection. Achondroplasia is caused by a recurrent gain-of-function mutation in FGFR3 (most commonly G380R), which constitutively activates downstream MAPK (RAS/RAF/MEK/ERK) signaling in growth-plate chondrocytes. Over-active MAPK suppresses chondrocyte proliferation, differentiation, and hypertrophy, blunting endochondral ossification — the process by which long bones lengthen at the growth plate during childhood. NPR-B activation by vosoritide triggers guanylyl-cyclase-mediated cGMP production in the same chondrocytes. cGMP inhibits the RAF–MEK–ERK axis downstream of FGFR3, effectively antagonizing the over-active FGFR3 signal at the MAPK node. The result is partial restoration of chondrocyte proliferation and differentiation, longer resting and proliferative zones at the growth plate, and increased linear bone growth. The effect is limited to children with open growth plates; once epiphyseal closure occurs, NPR-B-driven chondrocyte signaling is no longer available as a therapeutic lever.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vosoritide:

• 01Final adult height outcomes for children starting treatment in infancy under the 2023 indication expansion — those children have not yet completed growth.
• 02Effect on non-stature complications of achondroplasia (foramen magnum stenosis, spinal stenosis, sleep apnea, otitis media) — a 2026 pooled analysis of 230 trial participants found complication prevalence consistent with or lower than untreated natural-history rates, but this is observational and not yet confirmed in controlled long-term data.
• 03Optimal duration of therapy and optimal age to start — whether treating from earliest infancy yields proportionally greater adult-height gain than starting at age 5 is a key empirical question still accumulating data.
• 04Head-to-head comparisons — there are none yet against once-weekly navepegritide (YUVIWEL, US accelerated approval February 2026; +1.49 cm/year over placebo) or oral infigratinib, an FGFR1-3 tyrosine kinase inhibitor (+1.74 cm/year in Phase 3 PROPEL 3), and the trials enrolled different age ranges. BioMarin's ASPEN trial is testing its weekly long-acting CNP, BMN 333, directly against vosoritide.
• 05Benefit and risk in other growth disorders — vosoritide is being tested in hypochondroplasia (positive Phase 3), idiopathic short stature, Noonan syndrome, and Turner syndrome, and in investigator-led trials some children with Turner syndrome, ACAN, or RASopathy variants developed slipped capital femoral epiphysis or knock-knees, so the balance may differ by condition.
• 06Quality-of-life and functional outcomes — growth velocity is the regulatory endpoint, but what matters to families is broader (function, complications, psychosocial outcomes); validated outcome measures in this domain are still maturing.
• 07Safety signals at long exposures and in larger populations — post-marketing surveillance will continue to characterize rare adverse events and long-term outcomes.

Forms & Administration

Voxzogo is supplied as a lyophilized powder for reconstitution into a small-volume subcutaneous injection, dosed once daily based on body weight (approximately 15 mcg/kg, with a weight-based dose table in the label). Injection is performed at home by a caregiver, typically in the upper arm, thigh, abdomen, or buttock, after training by the prescribing specialist and specialty pharmacy. All injectable peptides in children should only be administered under the guidance of a qualified healthcare provider; injection technique, dose preparation, and adverse-event monitoring are taught and reinforced through the Voxzogo patient support program.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

All dosing, initiation, and monitoring decisions for a child with achondroplasia should be made by a qualified pediatric specialist. The numbers above describe the FDA-labeled approach; individual dosing and continuation decisions require medical evaluation.

Timeline of Effects

Common Questions

Who Vosoritide Is NOT For

Drug & Supplement Interactions

Formal drug-interaction studies for vosoritide are limited because the target population is pediatric and most children with achondroplasia are not on extensive concomitant medications. The label says it is broken down by catabolic pathways into small peptide fragments and amino acids; in laboratory studies it neither inhibits nor induces CYP450 enzymes, and no clinical interaction studies have been done. The main theoretical interaction concern is additive blood-pressure-lowering with other agents that reduce blood pressure. Because CNP-family peptides have vasorelaxant activity via NPR-B-driven cGMP, concurrent antihypertensive medications, nitrates, phosphodiesterase-5 inhibitors, or other vasodilators could compound transient reductions in blood pressure. In the pediatric achondroplasia population this is rarely clinically relevant, but the label notes that children with significant heart or vascular disease and those on blood-pressure medicines were excluded from the trials and the Voxzogo dosing strategy (administered with a meal or snack, ensuring adequate hydration) is designed to minimize the risk of symptomatic hypotension. Families should disclose all concomitant medications, over-the-counter products, and supplements to the prescribing specialist and to the specialty pharmacy managing dispensation.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions